BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Autoimmunity
,
Valproic acid
,
rs4950928
,
PPARA
,
Coagulation
,
Inflammatory disorder
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
CDK4 6
Summary
General Info
Curated Studies
Most Correlated Studies
HeLa cells after G0-G1 / G1-S arrest release with CDK4/6 shRNA and IL-1a treated
Affects of CCND1 and CDK4/6 knockdown in breast cancer cell line MDA-MB-231
Breast cancer V720 cells treated with CDK4/6 inhibitor PD 0332991
Pancreatic ductal adenocarcinoma AsPC-1 and COLO-357 cells treated with CDK4 6 inhibitor PD 0332991
T-ALL cell line KOPTK1 treated with CDK4/6 inhibitor PD 0332991
Explore Curated Studies Results
Literature
Most Relevant Literature
CDK6 inhibits de novo lipogenesis in white adipose tissues but not in the liver.
Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.
CDK6: an attractive therapeutic target for T-ALL/LBL.
Predicting drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forwa…
Development of PROTAC degrader probe of CDK4/6 based on DCAF16.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumo…
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced…
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II T…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ